Skip to main content
AkademIndex

Products

For developers

AkademBaseOpen API for the ecosystem
← Back to work

Works cited by this work

171 works

Work: Exploring cellular immunotherapy platforms in multiple myeloma

  1. Nano based drug delivery systems: recent developments and future prospects

    Jayanta Kumar Patra, Gitishree Das, Leonardo Fernandes Fraceto +9

    Review article201811 citations
    ABI

  2. Neoantigens: promising targets for cancer therapy

    Na Xie, Guobo Shen, Wei Gao +3

    Review article20236 citations
    ABI

  3. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

    Nikhil C. Munshi, Larry D. Anderson, Nina Shah +25

    Article20215 citations
    ABI

  4. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma

    Noopur Raje, Jesús G. Berdeja, Yi Lin +20

    Article20194 citations
    ABI

  5. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management

    S. Vincent Rajkumar

    Article20224 citations
    ABI

  6. Bispecific T‐cell engagers for cancer immunotherapy

    Amelia M. Huehls, Tiffany A. Coupet, Charles L. Sentman

    Review article20143 citations
    ABI

  7. Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model

    Jaya Lakshmi Thangaraj, Seo-Yeon Ahn, Sung‐Hoon Jung +12

    Article20213 citations
    ABI

  8. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

    Jianjun Chu, Youcai Deng, D.M. Benson +13

    Article20133 citations
    ABI

  9. <i>In vivo</i> kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection

    Yan Zhang, Diana L. Wallace, Catherine M. de Lara +8

    Article20073 citations
    ABI

  10. Clinical relevance of host immunity in breast cancer: from TILs to the clinic

    Peter Savas, Roberto Salgado, Carsten Denkert +4

    Review article20153 citations
    ABI

  11. CS1 (SLAMF7, CD319) is an effective immunotherapeutic target for multiple myeloma.

    Joseph D. Malaer, Porunelloor A. Mathew

    Article20173 citations
    ABI

  12. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Stephen J. Schuster, Michael Bishop, Constantine S. Tam +21

    Article20183 citations
    ABI

  13. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors

    Na Tang, Chen Cheng, Xingying Zhang +6

    Article20203 citations
    ABI

  14. CAR-NK cells: A promising cellular immunotherapy for cancer

    Guozhu Xie, Han Dong, Yong Liang +3

    Review article20203 citations
    ABI

  15. Bispecifics, trispecifics, and other novel immune treatments in myeloma

    Guido Lancman, Joshua Richter, Ajai Chari

    Review article20203 citations
    ABI

  16. Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy

    Ying Gong, Roel G. J. Klein Wolterink, Jianxiang Wang +2

    Review article20213 citations
    ABI

  17. Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial

    Ben Creelan, Chao Wang, Jamie K. Teer +23

    Article20213 citations
    ABI

  18. Antibody drug conjugate: the “biological missile” for targeted cancer therapy

    Zhiwen Fu, Shijun Li, Sifei Han +2

    Review article20223 citations
    ABI

  19. Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer

    Feifei Li, Sheng Liu

    Review article20223 citations
    ABI

  20. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

    Leonid Cherkassky, Aurore Morello, Jonathan Villena‐Vargas +5

    Article20162 citations
    ABI

  21. CAR-T cells and combination therapies: What’s next in the immunotherapy revolution?

    María C. Ramello, Eric B. Haura, Daniel Abate‐Daga

    Article20172 citations
    ABI

  22. The Next Generation of Cellular Immunotherapy: Chimeric Antigen Receptor-Natural Killer Cells

    Jake Moscarelli, David J. Zahavi, Rachael Maynard +1

    Review article20222 citations
    ABI

  23. Anti-BCMA Dual Epitope-Binding CAR-Marrow Infiltrating Lymphocytes (MILs) Could Offer a Potent Innovative Immunotherapeutic Tool Against Multiple Myeloma

    Manh-Cuong Vo, Sunghoon Jung, Van‐Tan Nguyen +6

    Article20232 citations
    ABI

  24. Harnessing Nanotechnology: Emerging Strategies for Multiple Myeloma Therapy

    Min Yang, Yu Chen, Li Zhu +5

    Review article20242 citations
    ABI

  25. Ex vivo pulsed dendritic cell vaccination against cancer

    Yangzhuo Gu, Xing Zhao, Xiangrong Song

    Review article20202 citations
    ABI